Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer

NCT00010192 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
30
Enrollment
NIH
Sponsor class

Conditions

Interventions

Sponsor

National Cancer Institute (NCI)